DAVID YEE, M.D.
Medical Practice at Lake City Way, Seattle, WA
License number
Washington 056003
Category
Medical Practice
Type
Ophthalmology
License number
Washington MD00044375
Category
Medical Practice
Type
Ophthalmology
Address
Address
12750 Lake City Way NE, Seattle, WA 98125
Phone
(425) 283-1920
(425) 283-5401 (Fax)
(425) 283-5401 (Fax)
Organization information
See more information about DAVID YEE at bizstanding.comDavid Yee MD
12750 Lk City Way NE, Seattle, WA 98125
Industry:
Ophthalmology
Phone:
(206) 364-6060 (Phone)
David Thomas Yee
Professional information
Dr. David Yee, Bellevue WA - MD (Doctor of Medicine)
Specialties:
Ophthalmology
Address:
Richard F Yee MD
14505 Bel Red Rd STE 100, Bellevue 98007
(425) 283-1920 (Phone)
David T Yee MD
12750 Lake City Way NE, Seattle 98125
(206) 364-6060 (Phone)
14505 Bel Red Rd STE 100, Bellevue 98007
(425) 283-1920 (Phone)
David T Yee MD
12750 Lake City Way NE, Seattle 98125
(206) 364-6060 (Phone)
Languages:
English
Hospitals:
Richard F Yee MD
14505 Bel Red Rd STE 100, Bellevue 98007
David T Yee MD
12750 Lake City Way NE, Seattle 98125
Northwest Hospital & Medical Center
1550 North 115Th St, Seattle 98133
14505 Bel Red Rd STE 100, Bellevue 98007
David T Yee MD
12750 Lake City Way NE, Seattle 98125
Northwest Hospital & Medical Center
1550 North 115Th St, Seattle 98133
Education:
Medical School
University of Louisville
Graduated: 1992
University of Louisville
Graduated: 1992
David Yee
Location:
Greater Seattle Area
Industry:
Medical Practice
Skills:
Teaching, Healthcare, Surgery, Research, Healthcare Management, Hospitals
Protease-Activated Receptor Par4 Zchemr2
US Patent:
6436400, Aug 20, 2002
Filed:
Jan 7, 2000
Appl. No.:
09/479130
Inventors:
Wen-feng Xu - Mukilteo WA
Scott R. Presnell - Seattle WA
David P. Yee - Seattle WA
Donald C. Foster - Seattle WA
Scott R. Presnell - Seattle WA
David P. Yee - Seattle WA
Donald C. Foster - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
University of Washington - Seattle WA
University of Washington - Seattle WA
International Classification:
C07K 1628
US Classification:
4241431, 53038822
Abstract:
The present invention relates to polynucleotide and polypeptide molecules for PAR4, a novel member of the protease-activated receptor family. The polypeptides, and polynucleotides encoding them, mediate biological responses and/or cellular signaling in response to proteases. Protease cleavage of PAR4 exposes a PAR4 extracellular amino terminal portion that serves as a ligand for the PAR4 receptor. PAR4 may be used as a target in drug screening, and further used to identify proteinaceous or non-proteinaceous PAR4 agonists and antagonists. The present invention also includes antibodies to the PAR4 polypeptides.
David Yee
Location:
Greater Seattle Area
Industry:
Computer Software
Human Transcription Factor Zgcl-1
US Patent:
6420525, Jul 16, 2002
Filed:
Aug 19, 1998
Appl. No.:
09/137223
Inventors:
David P. Yee - Seattle WA
Theresa A. Deisher - Seattle WA
Theresa A. Deisher - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
C07K 1447
US Classification:
530350
Abstract:
Novel ZGCL-1 transcription factor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides, agonists and antagonists may be used within methods for promoting the proliferation and/or differentiation of testis cells, and may also be used in the development of male-specific contraceptives and infertility treatments.
Protese-Activated Receptor Par4 (Zchemr2)
US Patent:
6111075, Aug 29, 2000
Filed:
Apr 1, 1998
Appl. No.:
9/053866
Inventors:
Wen-feng Xu - Mukilteo WA
Scott R. Presnell - Seattle WA
David P. Yee - Seattle WA
Donald C. Foster - Seattle WA
Scott R. Presnell - Seattle WA
David P. Yee - Seattle WA
Donald C. Foster - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
C07K 706, C07K 708, C07K 14705
US Classification:
530350
Abstract:
The present invention relates to polynucleotide and polypeptide molecules for PAR4, a novel member of the protease-activated receptor family. The polypeptides, and polynucleotides encoding them, mediate biological responses and/or cellular signaling in response to proteases. Protease cleavage of PAR4 exposes a PAR4 extracellular amino terminal portion that serves as a ligand for the PAR4 receptor. PAR4 may be used as a target in drug screening, and further used to identify proteinaceous or non-proteinaceous PAR4 agonists and antagonists. The present invention also includes antibodies to the PAR4 polypeptides.
Protease-Activated Receptor Par4 (Zchemr2)
US Patent:
7122342, Oct 17, 2006
Filed:
Aug 10, 1999
Appl. No.:
09/371333
Inventors:
Wen-feng Xu - Mukilteo WA, US
Scott R. Presnell - Seattle WA, US
David P. Yee - Seattle WA, US
Donald C. Foster - Seattle WA, US
Scott R. Presnell - Seattle WA, US
David P. Yee - Seattle WA, US
Donald C. Foster - Seattle WA, US
Assignee:
ZymoGenetics, Inc. - Seattle WA
University of Washington - Seattle WA
University of Washington - Seattle WA
International Classification:
C12N 15/12
US Classification:
435 691, 4352523, 4353201, 536 235
Abstract:
The present invention relates to polynucleotide and polypeptide molecules for PAR4, a novel member of the protease-activated receptor family. The polypeptides, and polynucleotides encoding them, mediate biological responses and/or cellular signaling in response to proteases. Protease cleavage of PAR4 exposes a PAR4 extracellular amino terminal portion that serves as a ligand for the PAR4 receptor. PAR4 may be used as a target in drug screening, and further used to identify proteinaceous or non-proteinaceous PAR4 agonists and antagonists. The present invention also includes antibodies to the PAR4 polypeptides.